Siris Medical, Inc.

Siris Medical, Inc. provides AI-driven decision-making solutions specifically for oncology, aiming to optimize clinical workflows and enhance patient outcomes through advanced technology. Siris Medical, Inc. is focused on delivering AI-enabled oncology solutions.

Founded in 2013 in Burlingame, US, the company raised USD 4. 000 mn in Series A funding on September 8, 2017, from DigiTx Partners and Medical Technology Venture Partners. The company operates independently and has not undergone significant changes in its business strategy since its inception. Colin Carpenter serves as the CEO.

Siris Medical specializes in AI-enabled decision-making solutions for oncology, with its core product, InsightRT, analyzing over 10 million clinical images and 30,000 expert treatments. This solution allows oncologists to tailor treatment plans based on patient characteristics, primarily benefiting healthcare providers and payers. The services focus on the U. S.

market but have potential applications in other healthcare systems that prioritize personalized oncology care. Siris Medical generates revenue through subscription-based models and collaborations with healthcare providers and payers. The integration of InsightRT into clinical workflows leads to improved patient care and operational efficiency. The pricing structure is based on tiered subscription plans tailored to the size and needs of healthcare institutions, with InsightRT being central to these transactions.

Siris Medical plans to leverage the recent Series A funding of USD 4. 000 mn, secured in September 2017, to enhance product development and expand into new markets. The company is focusing on designing new product features for InsightRT, aiming for a launch in the next 12-18 months. Additionally, expansion efforts are directed towards international markets that prioritize personalized oncology solutions, targeting specific regions by 2025.